-transparent.png){kind=logo}
Accumulation of advanced glycation endproducts (AGE) in the brain is a feature of ageing and degeneration, especially in Alzheimer's disease (AD). Increased AGE levels explain many of the neuropathological and biochemical features of AD such as extensive protein crosslinking (beta-amyloid and MAP-tau), oxidative stress and neuronal cell death. Oxidative stress and AGEs initiate a positive feedback loop, where normal age-related changes develop into a pathophysiological cascade. Combined intervention using antioxidants, metal chelators, anti-inflammatory drugs and AGE-inhibitors may be a promising neuroprotective strategy.
Related Publications
G Münch, and
J Thome, and
P Foley, and
R Schinzel, and
P Riederer
April 2002,
Neuroreport,
G Münch, and
J Thome, and
P Foley, and
R Schinzel, and
P Riederer
May 2011,
Neurobiology of aging,
G Münch, and
J Thome, and
P Foley, and
R Schinzel, and
P Riederer
June 1998,
Brain research,
G Münch, and
J Thome, and
P Foley, and
R Schinzel, and
P Riederer
June 2005,
Current drug targets. CNS and neurological disorders,
G Münch, and
J Thome, and
P Foley, and
R Schinzel, and
P Riederer
February 2013,
Current opinion in lipidology,
G Münch, and
J Thome, and
P Foley, and
R Schinzel, and
P Riederer
January 1998,
Vascular medicine (London, England),
G Münch, and
J Thome, and
P Foley, and
R Schinzel, and
P Riederer
January 1998,
Journal of neural transmission (Vienna, Austria : 1996),
G Münch, and
J Thome, and
P Foley, and
R Schinzel, and
P Riederer
November 2001,
Brain research,
G Münch, and
J Thome, and
P Foley, and
R Schinzel, and
P Riederer
February 2002,
Journal of internal medicine,
G Münch, and
J Thome, and
P Foley, and
R Schinzel, and
P Riederer
February 2003,
Current rheumatology reports,
